---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001969"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:52:17.521818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alector Q4 2021 net loss $55.6M; cash $735M plus $200M from GSK; pipeline advancing

## Summary
- Net loss Q4 2021 $55.6M ($0.68/share) vs $52.2M ($0.66) in Q4 2020; full-year net loss $36.3M ($0.45) vs $190.2M ($2.45).
- Collaboration revenue Q4 $14.0M (up from $4.9M); full-year $207.1M (up from $21.1M) driven by GSK deal.
- Cash $735.3M at Dec 31, 2021; plus $200M from GSK in Jan 2022. Cash runway expected into mid-2024.
- AL002 Phase 2 ARIA observed; protocol amended to exclude APOE e4/e4 homozygotes.
- Appointed Sara Kenkare-Mitra (President/Head R&D) and Marc Grasso (CFO).

## SEC filing metadata
- accession: 0000950170-22-001969
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017022001969/0000950170-22-001969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017022001969/alec-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001969
- JSON: https://secwatch.observer/filing/0000950170-22-001969.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.